Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
Globe Newswire (Tue, 11-Aug 4:01 PM ET)
Mobia Medical Appoints Myriam Curet, M.D., to its Board of Directors
Globe Newswire (Mon, 3-Aug 4:05 PM ET)
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
Globe Newswire (Tue, 21-Jul 9:00 AM ET)
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
Globe Newswire (Mon, 20-Jul 8:31 AM ET)
Stereotaxis Completes Acquisition of Robocath
Globe Newswire (Thu, 9-Jul 8:08 AM ET)
Market Chameleon (Tue, 6-Jan 5:33 AM ET)
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Stereotaxis trades on the AMEX stock market under the symbol STXS.
As of August 28, 2026, STXS stock price declined to $1.46 with 160,073 million shares trading.
STXS has a beta of 1.85, meaning it tends to be more sensitive to market movements. STXS has a correlation of 0.21 to the broad based SPY ETF.
STXS has a market cap of $146.30 million. This is considered a Micro Cap stock.
Last quarter Stereotaxis reported $8 million in Revenue and -$.05 earnings per share. This fell short of revenue expectation by $-910,000 and missed earnings estimates by -$.01.
In the last 3 years, STXS traded as high as $3.59 and as low as $1.24.
The top ETF exchange traded funds that STXS belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
STXS has underperformed the market in the last year with a return of -49.1%, while the SPY ETF gained +20.2%. In the last 3 month period, STXS fell short of the market, returning -27.4%, while SPY returned +2.8%. However, in the most recent 2 weeks STXS has outperformed the stock market by returning +5.8%, while SPY returned -1.1%.
STXS support price is $1.42 and resistance is $1.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STXS shares will trade within this expected range on the day.
